CD8A and neoplasm: In contrast to Rag-/- mice, rIL-7 treatment of OT-I-reconstituted Rag-/-IL-7R-/- mice did not improve anti-tumor CD8+ T cell responses (Fig 1B) indicating that direct effects of rIL-7 on CD8+ T cells are not sufficient for successful tumor rejection.